OnKure Therapeutics (OKUR) Competitors

$4.21 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.12 -0.09 (-2.14%)

As of 05/22/2026 06:18 PM Eastern

OKUR vs. WHWK, MGNX, ORMP, ABOS, and OGI

Should you buy OnKure Therapeutics stock or one of its competitors? MarketBeat compares OnKure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OnKure Therapeutics include Whitehawk Therapeutics (WHWK), MacroGenics (MGNX), Oramed Pharmaceuticals (ORMP), Acumen Pharmaceuticals (ABOS), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry.

How does OnKure Therapeutics compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Whitehawk Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.00 beat Whitehawk Therapeutics' score of -0.25 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OnKure Therapeutics' return on equity of -61.02% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Whitehawk Therapeutics has higher revenue and earnings than OnKure Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

Whitehawk Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 63.33%. OnKure Therapeutics has a consensus target price of $27.00, indicating a potential upside of 541.33%. Given OnKure Therapeutics' higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Whitehawk Therapeutics beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MacroGenics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

In the previous week, MacroGenics had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for OnKure Therapeutics. MacroGenics' average media sentiment score of 0.28 beat OnKure Therapeutics' score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MacroGenics currently has a consensus price target of $5.50, suggesting a potential upside of 21.41%. OnKure Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 541.33%. Given OnKure Therapeutics' higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OnKure Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.93	-$74.62M	-$1.10	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

OnKure Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. OnKure Therapeutics' return on equity of -61.02% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Summary

MacroGenics beats OnKure Therapeutics on 10 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

OnKure Therapeutics has a consensus target price of $27.00, indicating a potential upside of 541.33%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 1 mentions for OnKure Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 0.11 beat OnKure Therapeutics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	81.66	$64.05M	$2.59	1.54
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

Oramed Pharmaceuticals' return on equity of -5.37% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
OnKure Therapeutics	N/A	-61.02%	-55.99%

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats OnKure Therapeutics on 10 of the 13 factors compared between the two stocks.

How does OnKure Therapeutics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 9.3% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus price target of $6.67, suggesting a potential upside of 165.60%. OnKure Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 541.33%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acumen Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 1 mentions for OnKure Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 0.25 beat OnKure Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

OnKure Therapeutics' return on equity of -61.02% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Summary

OnKure Therapeutics beats Acumen Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does OnKure Therapeutics compare to Organigram Global?

OnKure Therapeutics (NASDAQ:OKUR) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 1 articles in the media. OnKure Therapeutics' average media sentiment score of 0.00 equaled Organigram Global'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organigram Global	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OnKure Therapeutics has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. Organigram Global's return on equity of -13.41% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Organigram Global	-9.22%	-13.41%	-9.09%

OnKure Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

OnKure Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 541.33%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Organigram Global has higher revenue and earnings than OnKure Therapeutics. Organigram Global is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Organigram Global	$185.07M	0.85	-$17.70M	-$0.13	N/A

Summary

Organigram Global beats OnKure Therapeutics on 8 of the 13 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$170.06M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.97	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.92	7.09	10.37	7.14
Net Income	-$59.52M	$24.45M	$3.57B	$335.98M
7 Day Performance	36.69%	5.45%	6.01%	3.56%
1 Month Performance	-12.29%	2.43%	3.52%	2.54%
1 Year Performance	95.81%	62.98%	34.13%	35.05%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	2.6022 of 5 stars	$4.21 flat	$27.00 +541.3%	+95.8%	$170.06M	N/A	N/A	N/A	Gap Down
WHWK Whitehawk Therapeutics	2.9357 of 5 stars	$3.92 +3.2%	$7.33 +87.1%	N/A	$187.92M	$7.14M	N/A	21
MGNX MacroGenics	2.2094 of 5 stars	$3.52 +19.3%	$5.40 +53.4%	+200.0%	$187.50M	$149.50M	N/A	430	High Trading Volume
ORMP Oramed Pharmaceuticals	1.8885 of 5 stars	$4.45 -3.7%	N/A	+88.2%	$186.86M	$2M	2.99	10	Gap Up
ABOS Acumen Pharmaceuticals	2.2529 of 5 stars	$2.48 -3.5%	$6.67 +168.8%	+146.1%	$185.63M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. WHWK, MGNX, ORMP, ABOS, and OGI

How does OnKure Therapeutics compare to Whitehawk Therapeutics?

Summary

How does OnKure Therapeutics compare to MacroGenics?

Summary

How does OnKure Therapeutics compare to Oramed Pharmaceuticals?

Summary

How does OnKure Therapeutics compare to Acumen Pharmaceuticals?

Summary

How does OnKure Therapeutics compare to Organigram Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. WHWK, MGNX, ORMP, ABOS, and OGI

How does OnKure Therapeutics compare to Whitehawk Therapeutics?

Do institutionals and insiders have more ownership in WHWK or OKUR?

Which has more volatility & risk, WHWK or OKUR?

Does the media favor WHWK or OKUR?

Is WHWK or OKUR more profitable?

Which has stronger valuation & earnings, WHWK or OKUR?

Do analysts prefer WHWK or OKUR?

Summary

How does OnKure Therapeutics compare to MacroGenics?

Do insiders & institutionals hold more shares of MGNX or OKUR?

Which has more volatility & risk, MGNX or OKUR?

Does the media favor MGNX or OKUR?

Do analysts prefer MGNX or OKUR?

Which has stronger earnings and valuation, MGNX or OKUR?

Is MGNX or OKUR more profitable?

Summary

How does OnKure Therapeutics compare to Oramed Pharmaceuticals?

Do analysts prefer ORMP or OKUR?

Which has more risk and volatility, ORMP or OKUR?

Does the media prefer ORMP or OKUR?

Which has preferable earnings & valuation, ORMP or OKUR?

Is ORMP or OKUR more profitable?

Do institutionals and insiders believe in ORMP or OKUR?

Summary

How does OnKure Therapeutics compare to Acumen Pharmaceuticals?

Do insiders & institutionals hold more shares of ABOS or OKUR?

Do analysts prefer ABOS or OKUR?

Which has more risk & volatility, ABOS or OKUR?

Does the media prefer ABOS or OKUR?

Which has stronger earnings & valuation, ABOS or OKUR?

Is ABOS or OKUR more profitable?

Summary

How does OnKure Therapeutics compare to Organigram Global?

Does the media refer more to OKUR or OGI?

Do insiders and institutionals have more ownership in OKUR or OGI?

Is OKUR or OGI more profitable?

Which has more risk and volatility, OKUR or OGI?

Do analysts prefer OKUR or OGI?

Which has stronger earnings & valuation, OKUR or OGI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools